Alopecia areata (AA) is an autoimmune hair loss disorder in which systemic disturbances have been described, but are poorly understood. To evaluate disease mechanisms, we examined gene expression in the blood of defined clinical subgroups (patchy AA persistent type, AAP, n ¼ 5; alopecia universalis, AU, n ¼ 4) and healthy controls (unaffected relatives, UaR, n ¼ 5; unaffected non-relatives, UaNR, n ¼ 4) using microarrays. Unsupervised hierarchical clustering separates all four patient and control groups, producing three distinct expression patterns reflective of 'inheritance', 'disease' and 'severity' signatures. Functional classification of differentially expressed genes (DEGs) comparing disease (AAP, AU) vs normal (UaR) groups reveals upregulation in immune response, cytokine signaling, signal transduction, cell cycle, proteolysis and cell adhesionrelated genes. Pathway analysis further reveals the activation of several genes related to natural killer-cell cytotoxicity, apoptosis, mitogen activated protein kinase, Wnt signaling and B-and T-cell receptor signaling in AA patients. Finally, 35 genes differentially expressed in AA blood overlap with DEGs previously identified in AA skin lesions. Our results implicate innate and adaptive immune processes while also revealing novel pathways, such as Wnt signaling and apoptosis, relevant to AA pathogenesis. Our data suggest that peripheral blood expression profiles of AA patients likely carry new biomarkers associated with disease susceptibility and expression.
Introduction
Alopecia areata (AA) is an autoimmune skin disorder typically characterized by the spontaneous onset of patchy hair loss of the scalp. Although 80% of patients present with a minimal number of patches (AA; patchy persistent, AAP or transient, AAT), 7% of cases progress in clinical severity to total scalp-hair loss (alopecia totalis; AT) or total body hair loss (alopecia universalis, AU). The prevalence of AA in the United States is reported to be 0.1-0.2% in the general population, with a lifetime risk of 1.7%. 1, 2 The histopathological hallmark of AA is the presence of a perifollicular and intrafollicular lymphocytic infiltrate. T lymphocytes (predominantly CD4 þ cells), as well as Langerhans cells, macrophages and natural killer (NK) cells are found in the dermal papilla and matrix of the involved hair follicles. 3, 4 Lymphocytic infiltration of the anagen hair bulb and dermal papilla is accompanied by aberrant expression of human leukocyte antigen class I and class II antigens and intercellular adhesion molecule-1 on the follicular epithelium, [5] [6] [7] highlighting the role of immune dysfunction as a crucial feature in AA pathogenesis.
The etiopathogenesis of AA is not completely understood. The most widely accepted hypothesis describes AA as a T-cell mediated autoimmune response targeting an unknown antigen in anagen-stage hair follicles. 8, 9 It has also been postulated that compromise of immune privilege in normal hair follicles, mediated in part by interferon-gamma (INF-g), 10 has a role in the susceptibility and pathogenesis of AA. 11, 12 Considerable evidence indicates that genetic elements have a significant role in the etiology of AA, as evidenced by the recent identification of a number of suggested susceptibility loci, 13 the high incidence of positive family history in affected individuals 14, 15 and high twin concordance rates. [16] [17] [18] [19] [20] Many epidemiologic studies have shown a higher prevalence of autoimmune diseases, such as vitiligo, thyroid disease and collagen vascular disease, in AA patients and unaffected relatives (UaR) 21, 22 suggesting a genetic predisposition to autoimmunity associated with familial background of AA. 23 These findings imply that systemic disturbances contribute to this T-cell dependent, organ-specific disease. Overall, AA is a complex, polygenic disease likely initiated by the interactions between genetic and environmental factors triggering the immune dysfunction that results in autoimmune hair loss.
Global gene-expression profiling by DNA microarray has become a valuable tool for the study of autoimmune and/or inflammatory diseases. 24 Microarray studies on organ-specific autoimmune diseases have advanced our understanding of autoimmune disease pathogenesis, and revealed targets for clinical biomarkers, prognostic factors and subtype distinction for individualized therapy. [25] [26] [27] Our recent microarray analysis in AA patient skin samples, 28 along with a previous microarray study in murine and human AA skin, 29 help to substantiate AA as a Th1-cell-mediated autoimmune disorder with a late secondary humoral response. No study, however, has previously used gene microarray technology as a large-scale screening tool to investigate gene regulatory alterations in the peripheral blood of AA patients. As with many organ-specific diseases, the systemic environment in AA patients is likely to be critical in the generation and regulation of the immune response and inflammatory cascade that is ultimately directed to hair follicles.
The aims of the present study were to (1) establish peripheral gene expression profiles associated with AA and AA subgroups and (2) examine AA-associated transcriptional signatures to identify functional pathways and genes relevant to AA. On the basis of the global microarray analysis in AA patients and healthy control blood, we report three distinct transcriptional signatures relevant to (i) the genetic predisposition to disease, (ii) the clinical expression of disease and (iii) the degree of phenotypic severity. Evaluation of each of these signatures implicates several immune-related and signaling pathways in AA pathogenesis.
Results
Unsupervised hierarchical clustering separates sample groups by familial inheritance, absence or presence of disease and clinical subtype We used Affymetrix U133 Plus 2.0 microarray chips (Affymetrix, Santa Clara, CA, USA) to generate gene expression profiles from buffy coat samples obtained in 5 alopecia areata, patchy persistent (AAP) patients, 4 alopecia universalis (AU) patients, 5 unaffected relatives (UaR) and 4 unaffected non-relatives (UaNR) ( Table 1) . To explore the similarities and differences in global gene expression patterns among the samples without a priori knowledge of sample identity, we used an unsupervised hierarchical clustering method using those 551 probe sets with the highest variation across samples. This unbiased approach was used to determine the extent to which global gene expression analysis can be used to distinguish clinically defined subgroups (class prediction), as well as identify novel or unexpected gene expression patterns (class discovery).
We report that unsupervised hierarchical clustering reveals distinct separation of AA patients from controls ( Figure 1 ). Upon further evaluation, three unique patterns emerge. First, our data reveal that AA patients and first-degree relatives of AA patients (AAP, AU and UaR) cluster distinctly from the healthy controls with no familial connection to AA (UaNR), conceivably producing an 'inheritance' signature. Second, within this 'inheritance' cluster, AAP and AU samples further separate from UaR controls, with the exception of a single AU ('AU 4') sample, to produce a 'disease' signature. Third, within the 'disease' cluster, AAP Figure 2 ). The 'inheritance' signature also exhibits the upregulation of several apoptosis-related genes, including TNF alpha, CASP1 It has been shown that overexpression of Bcl-2 and Bcl-xL, both upregulated in the 'inheritance' signature, leads to premature termination of anagen and catagen acceleration, resulting in hair follicle regression and alopecia. 30 A number of the genes that are upregulated in the 'inheritance' signature have previously been implicated in AA pathogenesis (TNF, TRAF1, CTLA4, IL1RN, ICAM1) 9,10 or other autoimmune diseases (NKTR, IL-6 signal transducer). 31, 32 These findings reflect an activated immune system in AA-prone individuals with enhanced inflammatory cytokine expression and the enhanced expression of genes promoting trans-endothelial cell migration.
Conversely, we observe the downregulation of antigen processing and presentation related genes, integrin signaling, keratinocyte differentiation and of multiple metabolic pathways. Hedgehog-signaling components, including PTCH1, IHH, PKA and FBXW11 (b-TrCP), are also underexpressed in the 'inheritance' cluster compared with UaNR.
See Supplemental Table 1 for full list of DEGs within the 'inheritance' gene signature with chromosomal locations.
The 'disease' signature reveals dysregulation of immune system, signal transduction, cell cycle and apoptosis-related genes To evaluate alterations in gene expression that are specific to AA patients we eliminated UaNR subjects from our next analysis, thus enriching our gene list for transcriptional changes directly associated with clinical disease. We find 882 DEGs distinguish the 'disease' cluster (AAP and AU) from unaffected relative controls (UaR), again on the basis of a 1% false-discovery rate and greater than þ /À2.5-fold change cutoff (Table 2) . Functional annotation and pathway analysis of the 'disease' signature DEGs reveals an enrichment of genes related to immune system, signal transduction, cell cycle and apoptosis-related pathways.
A total of 167 DEGs (152 up, 15 down) are involved in immune system processes, including T-and B-cell response, NK-cell cytotoxicity and cytokine/chemokine signaling ( Figure 3) . Several of these genes and pathways have a previously described role in AA pathogenesis, validating that our experimental approach is sufficiently sensitive to capture disease-relevant processes. 10, 33 Although it has been shown that NK cells aggregate perifollicularly in AA lesional skin 3, 4, 34 and peripheral blood, 35, 36 there is limited data regarding the role of NK cells in AA pathogenesis. Our data show an upregulation of NK-cell cytotoxicity in AA peripheral blood that, as suggested by others, 11, 12, 37 may promote the failure of hair follicle immune privilege.
We also documented increased levels of Th17 pathway-related genes, including IL-23 alpha subunit p19 (FC ¼ 2.6), IL-17 receptor A (FC ¼ 2.6), interleukin 12 receptor beta 1 (FC ¼ 6.7), and CCR2 (FC ¼ 3.5) in the disease signature. Th17, a newly described IL-17-producing, CCR2 þ /CCR5À helper T-cell subset, is being increasingly recognized as important in infection clearance and autoimmune tissue inflammation. Although we did not find the IL-17A/F gene itself to be upregulated, our data nonetheless provide support for enhanced Th17 pathway activity in AA blood.
We observe the dysregulation of 28 apoptosis-related genes that may (1) contribute directly to hair follicle degeneration and/or catagen induction and (2) amplify the apoptotic debris that generates antigens capable of stimulating the immune system. Apoptotic processes also have a role in modeling the architecture of the developing follicle epithelium during morphogenesis, and have a major role in the control of the hair growth cycle. 38, 39 These findings correlate with the pervasive shift of hair follicle cycling from anagen to catagen characteristic of involved follicles and the presence of pro-apoptotic programs we observed in AA lesional skin. 28 Several unanticipated ontologies are significantly upregulated in the 'disease' signature, including genes involved in lipid metabolism, innate immunity and G-protein signal transduction, with prominence of Rho-GTPase signaling ( Figure 3 ). Rho signaling has been identified as essential to many cellular functions, including immune system development and cell cycle control, 40 although its potential role in AA pathogenesis requires further study. Pathway analysis by DAVID database also identifies 28 upregulated genes within the 'disease' signature related to MAPK signaling and 17 genes in Wnt/b-catenin signaling. Wnt/b-catenin signaling is essential for hair follicle morphogenesis, the onset of hair cycling and regeneration. 41, 42 See Supplemental Table 2 for full list of DEGs that comprise the 'disease' gene signature.
The AA 'severity' signature reveals a more robust expression of immune response-related genes in AAP when compared with AU To uncover the factors mediating progression of clinical severity and disease extent, we compared the genes and pathways differentially expressed between AAP and AU. AAP samples expressed 144 transcripts that are upregulated and 320 transcripts that are downregulated relative to AU samples (Table 2 ). Functional annotations reveal that AAP patients express higher levels of genes involved in signal transduction (34 genes), general immune function (42 genes), cytokine/chemokine signaling (19 genes) and cell adhesion/motility (18 genes) (Figure 4) . We found relative upregulation of multiple cell adhesion molecules, including CXCR1, CXCL2, Peripheral blood gene expression in alopecia areata AB Coda et al L-selectin, P-selectin and cutaneous lymphocyte antigen, in AAP compared with AU. Cutaneous lymphocyte antigen, the major E-selectin ligand on human skinhoming T cells, shows the highest upregulation, implying a more active T-cell mediated immune reaction is operative in clinically 'less severe' AAP patients compared with individuals with clinically 'more severe' AU that is measurable in peripheral blood.
Pathway analysis reveals dysregulation in transforming growth factor-beta signaling (7 genes), apoptosis (15 genes) and Wnt signaling (7 genes) in AAP relative to AU. Significant upregulation of TGF-beta signaling in AAP is shown by increased expression of TGF-b2, TSP-1, LTBP-1 and ACVR1 compared with AU. Previous studies have shown TGF-b to be localized in the outermost layer of outer root-sheath cells and bulge region in normal hair follicles and, as noted above, this molecule has been implicated in the maintenance of immune privilege. 12, 43 Thus, decreased levels of TGF-b2 in AU relative to AAP may indicate a more extensive loss of hair follicle immune privilege in AU.
See Supplemental Table 3 for full list of DEGs that constitute the 'severity-specific' gene signature.
Comparison of differential gene expression in AA blood vs that in skin reveals a set of shared genes and pathways A total of 35 dysregulated genes in the AA blood 'disease' signature correspond to those genes found to be dysregulated in AA lesional skin in our own studies 28 and in others 29 ( Table 3 ). Several of these overlapping genes are involved in T-cell immunity, cell adhesion/leukocyte migration, stress response and protein metabolism and modification. These data may reflect that peripheral blood contains skin-homing lymphocytes, and their precursors, which exhibit changes in gene expression relevant to AA pathology ( Figure 5 ). As a result, AA blood DEGs within the 'disease' and 'inheritance' signatures overlapping with skin DEGs may represent good candidate markers for AA diagnosis and susceptibility, pending larger confirmatory studies and advances in proteomic AA studies.
Discussion
The study of complex diseases must confront two major confounding factors: (1) the interplay of genetic and environmental factors at work and (2) broad clinical heterogeneity between patients. In this study, we used global transcriptional analysis of peripheral blood by microarray to (a) determine molecular classification of disease and disease subtypes and (b) offer a comprehensive view of system-wide functional pathway disturbances relevant to disease susceptibility, clinical expression and severity in the largest known microarray study on AA to date. As with many organ-specific diseases, the overlying systemic environment is likely to be critical in the generation and regulation of the immune response that is directed to hair follicles, and therefore relevant to pathogenic events. Ultimately, these studies intend to facilitate the search for biomarkers relevant to the diagnosis, prognosis and treatment of AA.
Unsupervised hierarchical clustering of microarray data generated from peripheral blood reveals three distinct gene signatures in our analysis, providing a means for molecular classification through class prediction (assigning samples to known categories of disease) and class discovery (identifying new classes of samples). Clustering data exhibit class prediction by (1) clearly distinguishing AA patients from controls ('disease' signature)-a comparison with relevance for diagnosis and identifying possible biomarkers for disease diagnosis and (2) distinguishing clinically severe (AU) from milder (AAP) forms of disease ('severity' signature)-a comparison relevant for understanding clinical heterogeneity and disease prognosis.
Furthermore, unsupervised clustering reveals an unexpected 'inheritance' signature (class discovery) that seems to separate AA patients and individuals who are related to AA patients (and may be at risk of developing AA) from healthy unrelated individuals. The illumination of an 'inheritance' signature supports the premise of a genetic component underlying the etiopathogenesis of AA and suggests that peripheral blood gene expression These genes show opposite differential expression between AA skin and AA blood. 'Inheritance' signature is defined as upregulated pathways in AAP, AU and UaR as compared with UaNR. 'Disease' signature is defined as upregulated pathways in AAP and AU vs UaR. 'Severity' signature is defined as upregulated pathways in AAP as compared with AU. *Denotes dysregulated pathway in AA skin.
Peripheral blood gene expression in alopecia areata AB Coda et al may contain the underpinnings of susceptibility to AA. Previous studies have suggested a polygenic 'inheritance' model is operative in AA 9, 23, 44 but this is the first study revealing that transcriptional profiling of peripheral blood may reflect distinct patterns of heritability in AA. Larger scale studies involving immunohistopathology and protein levels will be needed to validate the existence of an 'inheritance' pattern with the potential to identify at-risk individuals.
Functional classification and pathway analysis of DEGs within the three AA-associated transcriptional signatures highlight genes and pathways disturbances with relevance to genetic susceptibility, disease induction and maintenance and disease severity and progression. Multiple dysregulated pathways (MAPK, Wnt, Polyubiquitination and G-protein signaling) overlap all three signatures, whereas disturbances in NK-cell immunity and apoptosis-related pathways exclusively overlap the 'inheritance' and 'disease' signatures. Some pathways are uniquely altered in the 'inheritance' (Hh signaling), disease (innate immunity) and severity (cell adhesion and TGF-beta signaling) signatures. Finally, the dysregulation of T-cell immunity, Wnt signaling, apoptosis and cell adhesion-related pathways found in transcriptional analyses of both AA patient blood and lesional skin suggest direct pathogenic links between systemic disturbances and peripheral pathology.
Four major pathway disturbances (MAPK, G-protein signaling, Wnt signaling and polyubiquitination) intersect all three comparisons, suggesting that these pathways may be relevant to many aspects of AA, including susceptibility, induction and severity progression. Upregulation of p38-MAP signaling components (MAP2K3 and MAPK11) and Rac2 in the 'inheritance' and 'disease' signatures indicate active Th1-cell differentiation and enhanced production of IFN-g, 45 supporting the importance of an active Th1-mediated immune response in AA. Rac2, essential in T-cell and integrin activation and development of Th1 cells, 46 also has a role in amplifying the production of IFN-g at the effector phase of the T-cell response. 44 This amplification of IFN-g may contribute to the underlying mechanisms related to loss of hair follicle immune privilege.
NK cells have recently gained momentum as contributors to the collapse of immune privilege, and thus AA pathogenesis. Although the 'inheritance' signature shows upregulation of intracellular components of NK-cell cytotoxicity (ZAP70, LAT, LFA-ICAM1), the 'disease' signature exhibits increased expression of perforin and NK-cell activating receptors (NKG2E, CD244/2B4 and FCGR3A). Alternatively, several NKcell activating receptors (CD94, NKG2D and NKG2E) were found to be downregulated in UaR samples when compared with UaNR (data not shown). These findings suggest the presence of hyperresponsive NK cells in AA patient blood, whereas the suppression of NK-cell activity may have a protective role in susceptible, but disease-free, relatives of AA patients (UaR). Future work assessing gene expression levels of multiplex AA families might reveal diagnostic or prognostic markers from this pathway for clinical use.
In the 'disease' signature, we found upregulation of GSK3b, p53, NLK, CtBP2 and components of the noncanonical Wnt/calcium pathway (CaMK2 and PPP3CA), all of which are known to inhibit canonical Wnt/bcatenin signaling through UDP-mediated b-catenin degradation. 47 Absence of b-catenin has been shown to impair anagen initiation and the ability of stem cells to drive differentiation of hair keratinocytes, instead leading to epidermal differentiation. 41 These findings may be associated with the decreased expression in AA lesional skin samples of WNT10B, which itself stimulates canonical Wnt signaling, 48 and BMP2, important in coordination of follicular cycling. 28, 49 Furthermore, downregulation of Hh components, such as PTCH1 and b-TrCP, as seen in our 'inheritance' signature, may confer an impaired ability to regenerate hair and promote anagen hair growth. Inhibition of Hh signaling components in adult skin also has been previously shown to prevent anagen hair growth and cycling. [50] [51] [52] Thus, individuals with a personal or family history of AA appear to harbor an inherent dysfunction in hair regeneration that may contribute to disease susceptibility. Coupled with previous work showing that Wnt signaling can promote wound healing and hair follicle regeneration, 53 our data suggest that an arrested follicular cycling and impaired follicular regeneration through impaired Hh and Wnt signaling may have a role in the pathogenesis and severity of AA, and should be a focus of future studies.
Unique to the 'disease' signature is the upregulation of genes involved in the innate immune response. The upregulation of genes involved in innate immunity may suggest that AA patients have an inappropriate immune and/or inflammatory response to normally innocuous stimuli leading to the initiation of disease. As previously suggested, AA is likely the result of polygenic alterations coupled with undetermined environmental stimuli that trigger AA in susceptible individuals. The prominent role of innate immunity has been previously implicated in the pathogenesis of autoimmune diseases, 54, 55 however its role in AA remains poorly understood.
Our data reveal several genes and pathways in peripheral blood that may be particularly relevant to disease severity and response to treatment. For example, a specific type 1 interferon (IFNA13) is expressed highly in AU samples. This correlates with upregulation of IFN-a inducible genes, IFI-15 and IRF7, in AA lesional skin compared with non-lesional skin. 28 Several case reports have described severe AA/AU as a side effect of interferon-a therapy for various diseases. [56] [57] [58] Furthermore, IFN-a has been shown to promote NK-cell cytotoxicity and promote autoimmune disease, 59 thus it is plausible that IFN-a may function as a systemic amplifier in terms of disease extent and severity of AA. We also report that expression of FK506-binding proteins (FKBP), such as FKBP4 and FKBP15, are downregulated in AU compared with AAP. Tacrolimus (FK506) tropical treatment has been shown to be efficacious in some patients with AA, 60 and is known to form a FK506-FKBP complex that binds to and blocks calcineurin. Several case reports have shown treatment failure of tacrolimus in severe AA/AU patients. [61] [62] [63] It may be that inadequate expression of FKBPs in a subset of AU patients contributes to therapeutic resistance to tacrolimus, revealing a potentially useful marker for therapeutic efficacy. Nevertheless, the limited number of patients within this study limits its direct translation to the bedside. Although several of these pathways and findings may be relevant to disease susceptibility, pathogenesis and severity, further validation with larger cohorts will be necessary to confirm mechanistic pathways and clinically relevant biomarkers.
We also show that despite representing a clinically 'less severe' phenotype, AAP shows evidence of a more active immune response than AU, based on both unsupervised clustering data and functional pathway analyses. AU samples group more closely to UaR samples than AAP samples, with one AU sample even clustering within the UaR group. One explanation for this potentially paradoxical finding may be that an absence of hair follicles in AU patients essentially removes the immune response stimulus that may be present in the clinically 'less severe' AAP. Alternatively, chronic inflammation and subsequent exhaustion of the immune response in AA may also help to explain our microarray results.
Overall, the data presented here are a key initial step for identifying diagnostic and prognostic markers of disease, establishing a molecular classification of defined AA clinical subtypes, and providing insights into disease mechanisms. The substantial number of DEGs between patients and controls underscores the clinical heterogeneity and multifactorial nature that characterizes AA, whereas the distinct identification of various subgroups through unsupervised hierarchical clustering highlights the utility of microarray analysis for disease classification and illuminating disease mechanisms. The clinical and pathogenetic significance of any of the newly identified markers remains unclear, and larger scale studies will be required to confirm key genes and mechanistic pathways identified in our study. In future work, it will be important to evaluate AA patients stratified by a comprehensive list of constant (for example, age of onset, human leukocyte antigen types or positive family history of AA) and variable (for example, disease activity or response to therapy) clinical parameters that are likely to affect gene expression profiles and provide clues to explain disease heterogeneity. The elucidation of increasingly specific transcriptional profiles, or 'fingerprints', assigned to clearly defined disease subgroups can be expected to facilitate the discovery of biomarkers relevant to disease classification, prognosis and response to therapy for individualization of treatment. 64, 65 Patients with less than 100% scalp hair loss for more than or equal to 1 year were classified as AA, patchy persistent (AAP). Patients with 100% scalp and body hair loss were classified as AU. AAP patients in this study had not progressed to AT (100% scalp hair loss and varying degrees of body hair loss) or AU before study. We included 18 subjects in this study (Table 1 ): 9 subjects with AA (5 AAP and 4 AU), 5 UaR and 4 UaNR. Apart from one patient who was treated with systemic corticosteroids ('AAP 5'), all other AA subjects were untreated at the time of sample collection. Written informed consent was obtained from all study subjects before venous blood draws. Buffy coat samples were isolated from fresh whole blood at the time of collection, stored at À80 1C and subsequently used for RNA extraction. Information regarding demographic data, AA disease manifestation, current medication and comorbid autoimmune diseases was obtained at the time of blood collection.
Materials and methods

Patient recruitment
RNA extraction
Total RNA was isolated from buffy coat samples using TRIzol reagent (Invitrogen, San Diego, CA, USA) per manufacturer's protocol. The aqueous phase was isolated and treated with DNase (Qiagen, Valencia, CA, USA). RNA was then purified using the RNeasy Mini kit (Qiagen). After purifying steps, RNA was eluted with RNase-free water. The purity and concentration of the final RNA product was analyzed by Nanodrop 100 spectrophotometry (Thermo Scientific, Waltham, MA, USA). RNA integrity was assessed by using an RNA Pico Chip with an Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA). Purified RNA was stored at À80 1C for up to 30 days until proceeding with the amplification step.
cDNA production, amplification, fragmentation and labeling of cDNA Purified RNA was used to produce first-and secondstrand cDNA using the WT-Ovation FFPE RNA Amplification system V2 (NuGEN, San Carlos, CA, USA) by PCR. Double-stranded cDNA was amplified according to manufacturer's instructions and purified by DNA Clean & Concentrator-25 spin columns (Zymo Research, Orange, CA, USA). Only cDNA of high purity (260/280 ratios: 1.75 -2.1) was used for this study. Fragmenting and labeling of cDNA was performed using FL-Ovation cDNA Biotin Module V2 (NuGEN). To assure the success of fragmentation and size distribution before proceeding with microarray hybridization, cDNA samples were bioanalyzed before and after fragmentation and labeling using an RNA 6000 NanoChip on the Agilent Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA).
Microarray analysis
Labeled cDNA samples were hybridized to Affymetrix HG-U133 Plus 2.0 chips (Affymetrix), and then stained on the Affymetrix Fluidics Station 750 and scanned by the Affymetrix GeneChip Scanner 3000. The U133 Plus 2.0 chip contains more than 54000 probe sets representing more than 33 000 well-characterized genes and Unigenes. The Affymetrix microarray suite 5.0 was used to obtain gene expression signal values for each gene. Each chip was scaled to an average intensity of 500 to adjust for minor variations in the overall intensity of hybridization. dChip (www.dchip.org) was then used for probe-(normalization and modeling) and high-level (hierarchical clustering and sample comparison) analysis. Expression values were log 2 transformed and then used to perform an unsupervised hierarchical clustering method using those 551 probe sets with the highest variation across samples. To compare samples and generate a list of DEGs, the following filtering criteria were used: (i) Benjamini-Hochberg procedure with a 1% false-discovery rate; (ii) greater than a þ /À2.5-fold change in the mean expression values between the experimental and control groups. Redundant probe sets for a single gene were then eliminated. Next, we used gene ontology terms to functionally annotate DEGs, and subsequently perform pathway discovery analysis using the DAVID (http://david.abcc.ncif-crf.gov/) website. Chromosomal mapping of 100 genes assessed for significance by generating P-values for all stretches containing p20 DEGs to assess the significance of 'gene proximity'. Significant stretches (of p20 genes) were filtered at Po0.01.
